A tale of two necessities: Breakaway technology versus diabetes

Drug Discovery Today

Volumn 8, Issue 13, 2003, Pages 561-562

  Brown, Matt ^a  

^a NONE

Author keywords

Biochemistry; Diabetes; Drug Discovery; HTS; Molecular Medicine; Pharmaceutical Science; PTP1B; Techniques Methods; Technology; Tethering; Tyrosine phosphatase

Indexed keywords

ANTIDIABETIC AGENT; CYSTEINE; INSULIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR;

BLINDNESS; DISULFIDE BOND; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HEALTH CARE NEED; HEART DISEASE; HUMAN; INHIBITION KINETICS; INSULIN BINDING; INSULIN SENSITIVITY; LIGAND BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PHARMACEUTICAL ENGINEERING; PROTEIN PROTEIN INTERACTION; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY;

EID: 0038719004     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02770-3     Document Type: Short Survey

References (3)

1. Erlanson D.A., et al. Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. J. Am. Chem. Soc. 125:2003;5602-5603.
2. Elchebly M., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 283:1999;1544-1548.
3. Erlanson D.A., et al. Site-directed ligand discovery. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9367-9372.